Opportunity assessment for functional RNA & protein arrays

Challenge: A UK university had developed a technology that permits the creation of surface-immobilized functional RNAs in a microarray format. The technology has the potential to impact both...
Learn More

Valuation of a novel oncology program to support fundraising and M&A opportunities

Challenge An early stage virtual company developing a siRNA knock-down technology to increase chemo-sensitivity of tumor cells had developed a specific formulation of its siRNA therapeutic using a...
Learn More

Supporting a PE Fund with Radiopharmaceutical Opportunity Mapping & Market Landscaping

Challenge A private equity fund which had successfully invested in the advanced biologics CDMO space was considering entering the radiopharmaceuticals CDMO space through investment in an established...
Learn More

Clinical development strategy in malignant melanoma

Challenge: A biopharma company asked Alacrita to provide expert input on the clinical development of a microbiome therapeutic (LBP, live biotherapeutic product) in the context of first line and...
Learn More

Characterizing the European commercial opportunity for a microbiome company

Challenge: A clinical stage microbiome company was developing a microbiome therapeutic for the treatment of recurrent C. Difficle infection (rCDI). The company was progressing through clinical...
Learn More

Interim medical director for MAA submission

Challenge: On behalf of a European pharmaceutical company, one of Alacrita’s professionals acted as medical director for the registration of a new agent in a neuroendocrine indication in territories...
Learn More

Developing vaccine products

Challenge The UK HIV Vaccines Consortium needed expert advice. The consortium was supporting and coordinating the development of several new HIV vaccines in academia. They needed guidance about which...
Learn More

Glycan biomarker discovery market research in North America

Challenge A glycan biomarker research company with a proprietary platform offering biomarker discovery and characterization, diagnostic development and commercialization asked Alacrita to help them...
Learn More

Applying to Early Access to Medicines (EAMS) at the MHRA

Challenge: Our client was developing oncolytic viruses for treating a rare form of brain cancer. Its lead product had been successfully evaluated in a Phase I dose-escalation study. Direct injection...
Learn More

EU value proposition and market access plan for orphan disease drug

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...
Learn More

Preclinical & clinical asset pipeline valuation

Challenge: A young biotech company with a portfolio of clinical and pre-clinical stage bispecific antibodies (BsAb) to treat various cancers was in the process of completing a Series A funding round....
Learn More

Regulatory strategy for a novel drug delivery technology

Challenge: Our client was developing a highly novel and versatile intracellular delivery vehicle which could readily penetrate cells without compromising membrane integrity or inducing cytotoxicity....
Learn More